Winkler K, Matzke E, Caspers S, Erttmann R, Grosch-Wörner I, Kabisch H, Müller J, Landbeck G
Klin Padiatr. 1981 May;193(3):155-8. doi: 10.1055/s-2008-1034451.
The cooperative study COALL-80 is derived from the BFM-78-study. The aim of the study is a reduction of the initial therapy-morbidity and -mortality without loss of efficacy by omitting asparaginase from the four drug-induction regimen and interposing it between induction- and CNS-therapy phase. The expected two years disease free survival rate of a pilot study will be 82%. This finding is hitherto comparable with the BFM-study results.